Arturo Estrella has a message for recession naysayers: It could hit sooner than you think.Marketsread more
Local governments commonly share single service providers, making many vulnerable at once. On top of this, ransomware has often been used to mask more targeted, malicious...Technologyread more
Salesforce released its first earnings report since its $15.3 billion acquisition of Tableau Software, the company's largest deal ever.Technologyread more
Fed Chairman Jerome Powell faces the tough challenge of presenting a unified voice on Fed policy from the most divided Fed in years.Market Insiderread more
Kudlow also confirmed to CNBC that he supported a tax cut proposal floated earlier Thursday by Sen. Rick Scott, R-Fla.Politicsread more
VMware is following through on its proposal to buy Pivotal, a fellow Dell subsidiary, and expanding into cybersecurity with the acquisition of Carbon Black.Technologyread more
Google says it shut down hundreds of YouTube channels tied to misinformation around the Hong Kong protests.Technologyread more
It is a rare scenario where long-term interest rates suddenly fall below short-term interest rates.Real Estateread more
Investors are rushing to get a piece of its privately held rival Impossible Foods before it goes public, according to the Wall Street Journal.Food & Beverageread more
Weisler has been CEO at the company since 2015 when it split from HPE.Technologyread more
Companies want to know our values and if they work with us, "they want to be aligned with those values," Salesforce co-CEO Keith Block says.Mad Money with Jim Cramerread more
Food and Drug Administration Commissioner Scott Gottlieb on Tuesday blamed high drug prices in part on the "wacky" system where pharmaceutical companies discount their medications but patients don't see those savings.
Drugmakers negotiate discounts, known as rebates, with pharmacy benefit managers in order to secure a spot on their formularies. Employers typically use these rebates to lower premiums for employees across the board rather than giving them to the patients who are paying for the drugs.
"[Patients are] spending money to subsidize everyone else's premium," Gottlieb said in an interview with CNBC's "Squawk Box. " "The sick people are helping to subsidize the healthy people. That's not how insurance is supposed to work. So we've got a wacky system where the discounts aren't flowing to the people."
Lawmakers are set to grill executives from seven drugmakers — AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck, Pfizer and Sanofi — on Tuesday at a Senate Finance Committee hearing. They are sure to ask about high list prices. Drug companies say these prices are merely starting points and that few people really pay list price.
Rebates are a favorite target of drug companies, who say pharmaceutical benefit managers extract huge discounts but keep them for themselves instead of sharing the savings with patients. The PBMs say it's drugmakers alone who set high prices.
The Trump administration has proposed that PBMs pass on an estimated $29 billion in rebates to consumers. Gottlieb said that by removing the middlemen's payments, the administration hopes drugmakers will cut list prices for drugs.
He said lawmakers could come together on legislation to address high drug prices.
"I think we're seeing a consensus emerge in Washington for some kind of bipartisan action," he said.
Senate Finance Committee Chairman Chuck Grassley, R-Iowa, in a separate interview said there's a "very good opportunity" for "bipartisan results and bipartisan legislation" to come out of the hearing.